@article{bouchard_multisite_2022,

title = {A Multisite Non-Inferiority Randomized Controlled Trial of the Efficacy of Cognitive-Behavior Therapy for Generalized Anxiety Disorder Delivered by Videoconference},

author = {S. Bouchard and M. J. Dugas and G. Belleville and F. Langlois and P. Gosselin and G. Robillard and G. Corno and A. Marchand},

url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85139777758&doi=10.3390%2fjcm11195924&partnerID=40&md5=52cbc697b3a9705b2f7fb87b7bfdc3eb},

doi = {10.3390/jcm11195924},

issn = {20770383 (ISSN)},

year  = {2022},

date = {2022-01-01},

journal = {Journal of Clinical Medicine},

volume = {11},

number = {19},

abstract = {Delivering psychotherapy by videoconference has been studied in a number of clinical trials, but no large controlled trial has involved generalized anxiety disorder (GAD). This multicenter randomized controlled non-inferiority trial was conducted to test if cognitive-behavior psychotherapy delivered by videoconference (VCP) is as effective as cognitive-behavior psychotherapy delivered face-to-face, using a strict margin of tolerance for non-inferiority. A total of 148 adults received a 15-session weekly manualized program. The treatment was based on the intolerance of uncertainty model of GAD. The impact of treatment was assessed using primary (GAD severity), secondary (worry, anxiety, and intolerance of uncertainty) and tertiary (general functioning) variables measured before and after treatment and at 6-month and 12-month follow-ups. Results showed that: (a) the treatment was effective; (b) VCP for GAD was statistically non-inferior to face-to-face psychotherapy on primary, secondary and tertiary measures at all assessment points; (c) change in intolerance of uncertainty significantly predicted change in the primary outcome measure over and above important clinical factors common to all psychotherapies (motivation, working alliance, perceived therapist competence, and client satisfaction). These findings support the use of VCP as a promising treatment option for adults with GAD. Clinical trial registry: ISRCTN#12662027. © 2022 by the authors.},

note = {Publisher: MDPI},

keywords = {adult, Anxiety, article, Beck Depression Inventory, cognitive behavioral therapy, Cognitive-behavior therapy, competence, controlled study, female, follow up, generalized anxiety disorder, Generalized Anxiety Disorder Scale, human, Likert scale, major clinical study, male, motivation, multicenter study, non-inferiority, patient worry, penn state worry questionnaire, predictors of outcome, psychotherapist, quality of life, randomized controlled trial, Structured Clinical Interview for DSM Disorders, treatment outcome, videoconferencing, videoconferencing psychotherapy, World Health Organization},

pubstate = {published},

tppubtype = {article}

}